Use of omalizumab to improve desensitization safety in allergen immunotherapy

J Allergy Clin Immunol. 2014 Mar;133(3):937-937.e2. doi: 10.1016/j.jaci.2013.12.1089.

Authors

Désirée Larenas-Linnemann¹, Ulrich Wahn², Matthias Kopp³

Affiliations

¹ Hospital Médica Sur, Colonia Toriello Guerra, Delegación Tlalpan, Mexico City, Mexico. Electronic address: [email protected].
² Department for Pediatric Pneumology and Immunology, Charité University of Medicine, Berlin, Germany.
³ Department of Pediatric Allergy and Pulmonology, University Luebeck, Airway Research-Center North (ARCN), Member of the "Deutsches Zentrums für Lungenforschung" (DZL), Lübeck, Germany.

PMID: 24581432
DOI: 10.1016/j.jaci.2013.12.1089

No abstract available

Publication types

Case Reports

MeSH terms

Adult
Anti-Asthmatic Agents / therapeutic use*
Antibodies, Anti-Idiotypic / therapeutic use*
Antibodies, Monoclonal, Humanized / therapeutic use*
Asthma / therapy*
Desensitization, Immunologic*
Female
Humans
Omalizumab

Substances

Anti-Asthmatic Agents
Antibodies, Anti-Idiotypic
Antibodies, Monoclonal, Humanized
Omalizumab